Humanigen is taking action on the novel coronavirus outbreak. Refer to this page for the latest educational resources and information on lenzilumab as a therapeutic for cytokine storm resulting from COVID-19 infection.

Follow us on Twitter

Learn how Lenzilumab may reduce serious or fatal outcomes in COVID-19 patients

Captions available (enable using video controls)
Available languages: English, Spanish (Español), Mandarin (國語), Cantonese (廣東話), Korean (한국어, 韓國語), French (Français), German (Deutsch), Italian (Italiano), Portuguese (Português)


Resources from Humanigen

Humanigen Investor Webinar: Results of the Initial Cohort of COVID-19 Patients Treated with Lenzilumab

June 16, 2020

Humanigen Reports Additional Analysis of Lenzilumab in Severe and Critical COVID-19 Patients

Read the Full Press Release

  • Twitter

©2020 Humanigen, Inc.  All rights reserved